Nasdaq
$169.00▲ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $22.41BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
51- 2d agoAfter-hours26.10.23 05:474Ownership#●●●
Guardant Health, Inc.
Roberto Mignone, an executive at Guardant Health, Inc., reported a change in beneficial ownership of securities on October 21, 2026. This filing serves as an official Form 4 statement detailing the executive's updated stock holdings.…more
$169.00+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 06:024Ownership
Guardant Health, Inc.
Insider Manuel Hidalgo Medina of Guardant Health, Inc. filed a Form 4 report regarding changes in beneficial ownership of securities as of October 17, 2026. This filing documents the updated equity holdings of the reporting insider.…more
$169.00+0.13%vs prev closeView filingShare - 5d agoAfter-hours26.10.20 06:024Ownership
Guardant Health, Inc.
Tariq Musa, an executive at Guardant Health, Inc., filed a Form 4 on October 19, 2026, to report changes in beneficial ownership of company securities that occurred on October 15, 2026. This filing serves as a standard disclosure of insider transaction activity.…more
$169.00+0.13%vs prev closeView filingShare
50 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15After-hours26.10.16 05:03#●●●
TwinStrand Biosciences Defeats Guardant Health's Patent Challenge
The U.S. Patent Trial and Appeal Board rejected Guardant Health's challenge to a core patent underlying TwinStrand's Duplex Sequencing technology. This ruling confirms the validity of the patent exclusively licensed to TwinStrand.…more
$169.00+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8After-hours26.10.09 05:14
●●●●●●●● ●●●●● ●●●●●●
Guardant Health's Guardant360 CDx has been approved in Europe as a companion diagnostic for AstraZeneca's therapy. This milestone is expected to facilitate earlier cancer mutation detection and improve patient outcomes.…more
$169.00+0.13%vs prev closeShareBenzinga - 10.5Regular26.10.06 00:30
●●●●●●●● ●●●●● ●●●●●●
Guardant Health announced that its Guardant Reveal blood test demonstrated 81% sensitivity for distant recurrence in resected stage II–III melanoma patients. The study confirms the test's clinical utility in identifying molecular residual disease and predicting recurrence risk post-surgery.…more
$169.00+0.13%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report